Barry-Wehmiller

In 1992, after departing from his role at L.A. Gear, retail visionary Robert Greenberg identified a gap in the footwear market: men needed stylish, comfortable street shoes that didn't compromise on either front. He founded Skechers in Manhattan Beach, California alongside his son Michael Greenberg, launching with a utility-focused men's boot called the Chrome Dome. What began as a single-category brand quickly evolved as Robert recognized that comfort wasn't just a feature - it was the foundation. This insight sparked a 30-year journey of innovation, transforming Skechers from a small startup into a global Fortune 500 powerhouse that would redefine how the world thinks about footwear. Today, Skechers operates as THE COMFORT TECHNOLOGY COMPANY®, designing, developing and marketing a diverse portfolio of lifestyle and performance footwear, apparel and accessories for men, women and children across approximately 180 countries. Through a sophisticated integrated infrastructure that includes LEED Gold-certified distribution centers in California, Belgium, China and India, plus more than 5,300 retail locations worldwide, Skechers has grown from that first logger boot into a complete lifestyle brand. The company's technologies - like podiatrist-certified Arch Fit developed from 20 years of data, hands-free Slip-ins, and award-winning Performance collections - demonstrate how a founding commitment to comfort innovation can become a global movement that connects millions of people to products that help them look and feel good.

Professionals face critical decisions every day where access to the right information can mean the difference between success and failure, compliance and violation, even life and death in healthcare settings. Wolters Kluwer exists to solve this fundamental challenge by combining nearly two centuries of deep domain expertise with intelligent technology to deliver expert information, software solutions, and services when professionals need them most. Today, Wolters Kluwer serves 93% of Fortune 500 companies, 90% of US academic medical institutions, and 100% of both the top 100 accounting firms and top 100 law firms in the United States. The company's solutions empower professionals across healthcare, tax and accounting, financial and corporate compliance, and legal and regulatory sectors to make informed decisions that drive their organizations forward while maintaining the highest standards of compliance and quality in their respective fields.

Stambaugh Ness operates at the intersection of compliance, tax strategy, and technology advisory for a sector with specific attack surfaces: architecture, engineering, and construction firms running project-based operations on Deltek ERP systems. Since 1918, the firm has specialized exclusively in AEC, which means their cybersecurity advisory practice isn't generic - it's built around the operational realities of distributed project teams, client data governance requirements, and the compliance frameworks that govern construction and engineering contracts. The technology stack centers on Deltek Ajera, Vantagepoint, and Vision - ERP platforms common in AEC that handle everything from project accounting to resource management. The firm also works within Microsoft Azure and Microsoft 365 environments, with Egnyte for file sharing and Teams for collaboration. The threat model here involves protecting project data across multiple stakeholders, securing financial systems tied to contract milestones, and maintaining compliance posture for clients subject to federal and state regulations. Stambaugh Ness is a remote-first organization hiring nationally, which means their security operations must account for a distributed workforce serving an equally distributed client base. Team members bring firsthand AEC experience, which translates to understanding how construction deadlines, bid processes, and multi-party project structures create operational constraints that security controls must accommodate rather than obstruct.

KraussMaffei is a global manufacturer of plastics and rubber processing machinery, operating 33 locations worldwide with approximately 4,200 employees across 57 nationalities. The company has been active for over 185 years and maintains technology portfolios spanning injection molding, extrusion, reaction process machinery, and additive manufacturing. Its customer base includes automotive, packaging, medical, construction, and household appliance manufacturers. The organization has committed to a 50% CO2 reduction target by 2030 and has invested more than three decades in plastic reuse research and development, focusing on recycling, upcycling, and recompounding technologies. From a security architecture perspective, KraussMaffei runs a Microsoft 365 environment with layered enterprise security controls. The infrastructure includes SIEM for threat detection and response, cloud security tooling, and PKI for identity and cryptographic operations. The perimeter and internal network security stack features firewalls, intrusion detection and prevention systems (IDS/IPS), cloud access security brokers (CASB) for SaaS visibility, and data loss prevention (DLP) controls. The company also deploys isEazy, suggesting investment in security awareness training across its global workforce. The threat model for an organization of this scale and industrial profile includes supply chain integrity risks, intellectual property protection across decades of R&D investment, operational technology security at manufacturing sites, and compliance requirements across multiple regulatory jurisdictions. The company's end-to-end technology coverage - from design through production machinery to digital service solutions - means security teams must address both IT and OT environments, protect proprietary manufacturing processes, and secure customer-facing digital platforms. CEO Alex Li leads the organization from headquarters in Germany.

We're a team of scientists, engineers, and computational chemists building software that transforms how drugs and materials are discovered. Founded in 1990, we started with a simple but ambitious idea: use physics-based simulations to predict molecular behavior with accuracy that could actually guide real-world research. Today, our platform combines molecular simulation with machine learning, helping pharmaceutical companies, biotech firms, and industrial researchers find promising molecules faster and more cost-effectively than traditional trial-and-error methods. What makes us different is that we're not just building software - we're actively applying these tools ourselves through drug discovery collaborations. We've seen our platform help researchers identify compounds they never would have considered, and we've watched computational predictions translate into real experimental results. Our team spans physics, chemistry, biology, and computer science, all working together to solve problems that sit at the intersection of these fields. We're proud to partner with over 1,600 organizations across 70 countries, and we're constantly pushing the boundaries of what's possible when you bring rigorous physics together with modern AI.

Merck Sharp & Dohme LLC operates as a research-intensive biopharmaceutical company with more than 130 years of operational history, developing medicines and vaccines for both human and animal health applications. Known as Merck & Co. in the United States and Canada, MSD maintains a global presence with what the company describes as one of the most diverse pharmaceutical pipelines in its history. The organization works across multiple technical domains including drug development, vaccine development, biopharmaceutical research, infectious disease research, and veterinary medicine, under CEO Robert M. Davis. The company's historical impact includes the development of streptomycin, an antibiotic credited with reducing tuberculosis deaths by nearly 50% by 1950. Current operations span human pharmaceuticals, vaccines, and a dedicated Animal Health division that addresses veterinary medicine, food safety, and agricultural protein supply challenges. MSD's technical focus areas include pharmaceutical pipeline development and public health initiatives, targeting what it characterizes as the world's most serious health concerns. For professionals evaluating biopharmaceutical organizations, MSD presents a large-scale research environment spanning infectious disease, drug discovery, and veterinary applications. The company operates under a stated philosophy that "medicine is for the people, not for the profits," though like all major pharmaceutical companies, it functions within commercial market structures. The scope of operations extends from basic research through clinical development to global distribution, requiring technical infrastructure to support complex supply chains, regulatory compliance systems, and data management across multiple therapeutic areas and geographic markets.